The development and breakaway of a compressible air jet with streamline curvature and its application to the coanda flare

This study concerns an underexpanded jet, issuing from a convergent slot into quiescent air, as it is deflected by a convex surface of constant radius. Emphasis Is placed on the mechanism of breakaway, a phenomenon whereby the jet leaves the surface tangentially. An optical system based on the standard Z-type Schlieren configuration and capable of interferometric, Schlieren and shadowgraph techniques has been designed. The techniques are interchanged simply, a laser source being employed for Interferometry and a Xenon spark source for Schlieren and shadowgraph. Vibrations limit the interferometry and improvements are discussed. Shadowgraph and both spark and continuous Schlieren techniques gave good results. Total pressure traverses and surface oil flow visualization show that the influence of secondary flows on breakaway is small. Measurements of the coefficient of discharge show an increase both as the stagnation pressure Is Increased and as the slot width is reduced. The existence of a separation bubble has been established from surface static pressure measurements and shadowgraph and Schlieren photographs. Surface oil flow visualization shows a region of reversed flow withhin the bubble. The bubble grows as the stagnation pressure Is increased and eventually causes breakaway. A potential flow calculation method using the method of characteristics has been developed. Calculation of a fully attached Jet is inaccurate because the separation bubble is ignored. A calculation using the measured surface static pressures accurately predicts the main features of the first shock cell. Reattachment occurs further downstream of the jet and its breakaway should involve a coupling of the solutions of the outer shear layer, potential core and separated boundary layer, the latter including reversed flow

Applications of electrodynamic tethers and the STEP-AIRSEDS mission

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/76415/1/AIAA-2001-1144-690.pd

Impact of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial

Background: Meningococcal conjugate vaccines protect individuals directly, but also confer herd protection by interrupting carriage transmission. This Phase III observer-blind, randomised, controlled study evaluated the effects of meningococcal quadrivalent (ACWY) glycoconjugate (MenACWY-CRM) or serogroup B (4CMenB) vaccination on meningococcal carriage rates in young adults. Methods: University students (aged 18–24 years) from ten sites in England were randomised to receive two vaccinations one month apart: two doses of Japanese Encephalitis vaccine (controls), two doses of 4CMenB (4CMenB), or one dose of MenACWY-CRM then placebo (MenACWY-CRM). Meningococci were isolated from oropharyngeal swabs collected before vaccination and at five scheduled intervals over one year. Primary analysis was cross-sectional carriage one month after the vaccine course; secondary analyses included comparison of carriage at any time point after primary analysis until study termination. Findings: 2954 subjects were randomised (control, n=987; 4CMenB, n=988; MenACWY-CRM, n=979); approximately one-third of each group was positive for meningococcal carriage at study entry. By one month, there was no significant difference in carriage between controls and 4CMenB (Odds Ratios (OR) [95% CI]; 1·2 [0·8−1·7]) or MenACWY-CRM (OR [95% CI], 0·9 [0·6–1·3]) groups. From three months after dose two, 4CMenB vaccination resulted in significantly lower carriage of any meningococcal strain (calculated efficacy 18·2% [95% CI: 3·4–30·8]) and capsular groups BCWY (calculated efficacy 26·6% [95% CI: 10·5–39·9]) compared to control vaccination. Significantly lower carriage rates were also observed in the MenACWY-CRM group compared with controls: calculated efficacies 39·0% [95%CI: 17·3-55·0] and 36.2% [95%CI: 15·6-51·7] for serogroups Y and CWY, respectively. Interpretation: MenACWY-CRM and 4CMenB vaccines reduced meningococcal carriage rates over 12 months post-vaccination and, therefore, may affect transmission where widely implemented

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial

Background: Meningococcal conjugate vaccines protect individuals directly, but also confer herd protection by interrupting carriage transmission. This Phase III observer-blind, randomised, controlled study evaluated the effects of meningococcal quadrivalent (ACWY) glycoconjugate (MenACWY-CRM) or serogroup B (4CMenB) vaccination on meningococcal carriage rates in young adults.Methods: University students (aged 18–24 years) from ten sites in England were randomised to receive two vaccinations one month apart: two doses of Japanese Encephalitis vaccine (controls), two doses of 4CMenB (4CMenB), or one dose of MenACWY-CRM then placebo (MenACWY-CRM). Meningococci were isolated from oropharyngeal swabs collected before vaccination and at five scheduled intervals over one year. Primary analysis was cross-sectional carriage one month after the vaccine course; secondary analyses included comparison of carriage at any time point after primary analysis until study termination.Findings: 2954 subjects were randomised (control, n=987; 4CMenB, n=988; MenACWY-CRM, n=979); approximately one-third of each group was positive for meningococcal carriage at study entry. By one month, there was no significant difference in carriage between controls and 4CMenB (Odds Ratios (OR) [95% CI]; 1·2 [0·8−1·7]) or MenACWY-CRM (OR [95% CI], 0·9 [0·6–1·3]) groups. From three months after dose two, 4CMenB vaccination resulted in significantly lower carriage of any meningococcal strain (calculated efficacy 18·2% [95% CI: 3·4–30·8]) and capsular groups BCWY (calculated efficacy 26·6% [95% CI: 10·5–39·9]) compared to control vaccination. Significantly lower carriage rates were also observed in the MenACWY-CRM group compared with controls: calculated efficacies 39·0% [95%CI: 17·3-55·0] and 36.2% [95%CI: 15·6-51·7] for serogroups Y and CWY, respectively.Interpretation: MenACWY-CRM and 4CMenB vaccines reduced meningococcal carriage rates over 12 months post-vaccination and, therefore, may affect transmission where widely implemented

Expert range maps of global mammal distributions harmonised to three taxonomic authorities

AimComprehensive, global information on species' occurrences is an essential biodiversity variable and central to a range of applications in ecology, evolution, biogeography and conservation. Expert range maps often represent a species' only available distributional information and play an increasing role in conservation assessments and macroecology. We provide global range maps for the native ranges of all extant mammal species harmonised to the taxonomy of the Mammal Diversity Database (MDD) mobilised from two sources, the Handbook of the Mammals of the World (HMW) and the Illustrated Checklist of the Mammals of the World (CMW).LocationGlobal.TaxonAll extant mammal species.MethodsRange maps were digitally interpreted, georeferenced, error-checked and subsequently taxonomically aligned between the HMW (6253 species), the CMW (6431 species) and the MDD taxonomies (6362 species).ResultsRange maps can be evaluated and visualised in an online map browser at Map of Life (mol.org) and accessed for individual or batch download for non-commercial use.Main conclusionExpert maps of species' global distributions are limited in their spatial detail and temporal specificity, but form a useful basis for broad-scale characterizations and model-based integration with other data. We provide georeferenced range maps for the native ranges of all extant mammal species as shapefiles, with species-level metadata and source information packaged together in geodatabase format. Across the three taxonomic sources our maps entail, there are 1784 taxonomic name differences compared to the maps currently available on the IUCN Red List website. The expert maps provided here are harmonised to the MDD taxonomic authority and linked to a community of online tools that will enable transparent future updates and version control

Crop Updates 2005 - Geraldton

This session covers seventeen papers from different authors 2005 Seasonal Outlook, David Stephens and Nicola Telcik, Department of Agriculture Horses for Courses – using the best tools to manage climate risk, Cameron Weeks, Mingenew-Irwin Group / Planfarm and Richard Quinlan, Planfarm Agronomy Global influences driving Australian agriculture, Tony Harman, Australian Government Department of Agriculture, Fisheries and Forestry Wheat yield and quality improvements – where have they come from and can we have more? Wal Anderson, Department of Agriculture Rotations for nematode management, Vivien A. Vanstone, Sean J. Kelly, Helen F. Hunter and Mena C. Gilchrist, Department of Agriculture Integrate strategies to manage stripe rust risk, Ciara Beard, Geoff Thomas, Robert Loughman, Kith Jayasena and Manisha Shenkar, Department of Agriculture Frequency of herbicide resistance in wild radish populations across the WA wheatbelt, Dr Michael Walsh, Mechelle Owen and Prof. Stephen Powels, University of Western Australia The incidence and severity of wild radish resistance in the NAR – results from an in-situ survey, Rob Grima and Andrew Blake, Elders Limited Stubble management: the pros and cons of different methods, Bill Bowden, Department of Agriculture, Mike Collins WANTFA Effectiveness of Zinc Application Methods in Wheat, Luigi Moreschi, CSBP Know your Mo, Douglas Hamilton, Department of Agriculture Atrazine contamination of groundwater in the agricultural region of Western Australia, Russell Speed1, Neil Rothnie2, John Simons1, Ted Spadek2, and John Moore1, 1Department of Agriculture, 2Chemistry Centre (W.A.) Comparison of canola varieties in the Northern Agricultural Region in 2004, Graham Walton Department of Agriculture Pasture rotations are a promising option for sandplain production, Nadine Eva, Department of Agriculture Zone management can improve profit on sandplain, Bindi Webb, Damian Shepherd, Department of Agriculture, David Forrester, Davejeff Farms, casuarinas via Geraldton, Peter Tozer, Department of Agriculture Crop leftovers: what’s in stubble for sheep? Roy Butler and Keith Croker, Department of Agriculture Realising Rural Equity, Nathan Windebank, Australian Agricultural Contracts Limite

Erratum to: Methods for evaluating medical tests and biomarkers

[This corrects the article DOI: 10.1186/s41512-016-0001-y.]

Implementation of corticosteroids in treating COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK:prospective observational cohort study

BACKGROUND: Dexamethasone was the first intervention proven to reduce mortality in patients with COVID-19 being treated in hospital. We aimed to evaluate the adoption of corticosteroids in the treatment of COVID-19 in the UK after the RECOVERY trial publication on June 16, 2020, and to identify discrepancies in care. METHODS: We did an audit of clinical implementation of corticosteroids in a prospective, observational, cohort study in 237 UK acute care hospitals between March 16, 2020, and April 14, 2021, restricted to patients aged 18 years or older with proven or high likelihood of COVID-19, who received supplementary oxygen. The primary outcome was administration of dexamethasone, prednisolone, hydrocortisone, or methylprednisolone. This study is registered with ISRCTN, ISRCTN66726260. FINDINGS: Between June 17, 2020, and April 14, 2021, 47 795 (75·2%) of 63 525 of patients on supplementary oxygen received corticosteroids, higher among patients requiring critical care than in those who received ward care (11 185 [86·6%] of 12 909 vs 36 415 [72·4%] of 50 278). Patients 50 years or older were significantly less likely to receive corticosteroids than those younger than 50 years (adjusted odds ratio 0·79 [95% CI 0·70–0·89], p=0·0001, for 70–79 years; 0·52 [0·46–0·58], p80 years), independent of patient demographics and illness severity. 84 (54·2%) of 155 pregnant women received corticosteroids. Rates of corticosteroid administration increased from 27·5% in the week before June 16, 2020, to 75–80% in January, 2021. INTERPRETATION: Implementation of corticosteroids into clinical practice in the UK for patients with COVID-19 has been successful, but not universal. Patients older than 70 years, independent of illness severity, chronic neurological disease, and dementia, were less likely to receive corticosteroids than those who were younger, as were pregnant women. This could reflect appropriate clinical decision making, but the possibility of inequitable access to life-saving care should be considered. FUNDING: UK National Institute for Health Research and UK Medical Research Council